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Objective: To investigate the effect of low blood glucose on thrombin generation and fibrin clot properties in type
2 diabetes (T2DM).
Methods: In 165 patients with T2DM and high cardiovascular risk, we measured ex vivo plasma fibrin clot
permeation [Ks], turbidity and efficiency of fibrinolysis including clot lysis time [t50%], together with thrombin
generation and platelet activation markers in relation to fasting blood glucose.
Results: As compared to patients in medium (4.5-6.0 mmol/l, n = 52) and higher (>6.0 mmol/l, n = 75) glucose
group, subjects with low glycemia (<4.5 mmol/l, n = 38) had lower Ks by 11% (p < 0.001) and 8% (p = 0.01), respectively,
prolonged t50% by 10% (p < 0.001) and 7% (p = 0.016), respectively, and higher peak thrombin generation by 21% and
16%, respectively (p < 0.001 for both). There were no significant differences in Ks and t50% between patients in medium
and higher glucose group. In the whole group, a J-shape relationship was observed between glycemia and the
following factors: peak thrombin generation, Ks and t50%. Only in patients with HbA1c < 6.0% (42 mmol/mol)
(n = 26) fasting glucose positively correlated with Ks (r = 0.53, P = 0.006) and inversely with t50% (r = −0.46, P = 0.02).
By multiple regression analysis, after adjustment for age, fibrinogen, HbA1c, insulin treatment and T2DM duration,
fasting glycemia was the independent predictor of Ks (F = 6.6, df = 2, P = 0.002), t50% (F = 8.0, df = 2, P < 0.001) and
peak thrombin generation (F = 13.5, df = 2, P < 0.0001).
Conclusions: In T2DM patients fasting glycemia <4.5 mmol/l is associated with enhanced thrombin formation and formation
of denser fibrin clots displaying lower lysability, especially when strict glycemia control was achieved (HbA1c<6.0%).
Keyword: Blood glucose, Cardiovascular diseases, Diabetes complications, Fibrin, HypoglycemiaBackground
Patients with type 2 diabetes who are at high risk of
cardiovascular (CV) events have increased morbidity
and mortality. The optimal treatment of hyperglycemia
in those patients is not yet established [1]. Surprisingly,
recent clinical trials have clearly demonstrated that
intensive glucose lowering treatment provides limited
benefits on CV and all cause mortality in patients with* Correspondence: grzegorz.gajos@uj.edu.pl
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unless otherwise stated.type 2 diabetes and CV disease [1] or might be even
harmful [1]. Treatment-related hypoglycemia has been
identified as a potential factor for worsening the progno-
sis in diabetes [2,3]. However, mechanisms underlying
limited benefits from intensive glucose lowering in type
2 diabetes patients with high CV risk are unclear. They
involve adrenergic activation [3], combined with several
atherogenic and pro-inflammatory effects [4,5]. It is
known that even mild asymptomatic hypoglycemia (ap-
proximately 58–69 mg/dL [3.2-3.8 mmol/L]) stimulates
counter regulatory hormones i.e. adrenaline, noradren-
aline and may adversely affect the prognosis not only in
patients with type 2 diabetes [3].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Analysis Of Diagnostic Criteria in Europe (DECODE)
study it was shown that the relation between mortality
and fasting blood glucose (FBG) concentration followed
a J-shaped curve both in people without diabetes and in
diabetic patients [6]. Compared with an FPG of 4.50–
6.09 mmol/l, subjects with FPG <4.50 mmol/l had higher
both cardiovascular and all-cause mortality [6]. Moreover,
it has also been recently demonstrated in the analysis by
the Emerging Risk Factors Collaboration that in a large
number of prospective studies of participants without dia-
betes the J-shaped associations exist between various gly-
cemia measures (including FBG) and CV risk [7].
Unfortunately, the knowledge of real incidence of
hypoglycemia or low glycemia in large clinical trials and
its clinical significance is limited, as they rely mainly on
symptomatic and self-reported episodes. It has been sug-
gested that the harm associated with repeated episodes
of hypoglycemia might counterbalance the potential
benefit of intensive glucose lowering treatment [8].
Several lines of evidence indicate that hyperglycemia
in type 2 diabetes results in several prothrombotic
changes, including unfavorable fibrin clot structure.
Dunn et al. [9] showed that clots formed by fibrinogen
purified from type 2 diabetes subjects free of clinically
overt CV disease had a denser, less porous structure
than those from control subjects. Both low (<5 mmol/l)
and high glucose concentrations (>10 mmol/l) were as-
sociated with unfavorable structural changes in fibrin
network that were largely driven by fibrinogen glycation
[9]. Resistance of fibrin clots to lysis in type 2 diabetes
may also result from decreased binding of tissue plas-
minogen activator (t-PA) and plasminogen to fibrin,
increased α2-antiplasmin cross-linking, [10] and increased
glycation of plasminogen leading to lower plasmin gener-
ation and protein-specific activity [11]. Several studies
demonstrated that enhanced platelet activation and
thrombin generation, together with altered fibrin clot
properties, could increase the risk of myocardial infarction
and stroke in type 2 diabetes [12-14]. Recently, it has been
shown that prolonged duration of type 2 diabetes, on top
of inadequate glycemia control, is associated with in-
creased thrombin formation and prothrombotic fibrin clot
phenotype [15]. Additionally, stable angina, previous myo-
cardial infarction (MI) or stroke, arterial hypertension,
current smoking and family history of MI adversely affect
fibrin clot formation and degradation [16,17].
To date, few studies have investigated the effects of
hypoglycemia on blood coagulation. It was previously
shown that insulin-induced severe hypoglycemia in
healthy subjects promotes platelet aggregation [18,19].
Adrenergic stimulation and plasma epinephrine release
were proven to be major determinants of platelet activa-
tion in insulin-induced severe hypoglycemia in type 2diabetes [20]. Enhanced thrombin generation and increased
plasma factor VIII activity induced by hypoglycemia were
observed in type 1 diabetes [21]. Higher plasma levels
of von Willebrand factor with increased blood viscosity
have been documented in response to insulin-induced
hypoglycemia without any changes in fibrinogen or fi-
brin degradation products [22]. Most of those studies
explored hemostatic effects of symptomatic insulin-
induced severe hypoglycemia. Of note, in a recent obser-
vation in type 2 diabetes patients severe hypoglycemia
induced during hyperinsulinemic clamp study provoked
prolonged (for at least 1 week) prothrombotic changes in
the fibrin network and enhanced inflammation, for at least
1 week [23]. Little is known about alterations to blood co-
agulation and fibrin clot properties in mildly decreased
glycemia in type 2 diabetes, especially in patients with
high cardiovascular risk.
Given the paucity of data on the effects of hypoglycemia
on blood coagulation, we tested the hypothesis that low
blood glucose, like hyperglycemia, unfavorably alters
thrombin generation, platelet activation and fibrin clot
properties in patients with type 2 diabetes and high CV
risk.
Materials and methods
We screened 255 consecutive stable patients with type 2
diabetes that was diagnosed according to the American
Diabetes Association criteria [24]. Only patients with
high CV risk defined as the presence of either atheroscler-
otic CV disease or 2 concomitant risk factors (arterial
hypertension, hyperlipidemia, obesity, current smoking,
family history of CV) were included. The exclusion criteria
were as follows: arterial or venous thromboembolic events
within the previous 6 months, current anticoagulant or
heparin therapy, known cancer, chronic inflammatory dis-
ease, liver injury (alanine and asparagine transaminase
>1.5 times above the upper limit of the reference range),
glomerular filtration rate (GFR) <30 mL/min, pregnancy,
all the states known to alter blood coagulation and/or fi-
brin clot structure [14,16].
Arterial hypertension was defined as a systolic and/
or a diastolic blood pressure measurement consist-
ently ≥140 mmHg or ≥90 mmHg, respectively. Dyslipid-
emia was defined as total cholesterol (TC) >5.0 mmol/L
and low-density lipoprotein (LDL) cholesterol >2.6 mmol/L
or ongoing lipid-lowering treatment. Obesity was diagnosed
when BMI ≥30 kg/m2. A positive family history was defined
as evidence of coronary artery disease (CAD) in a first de-
gree relative in men before the age of 55 years and women
before the age of 65 years. CAD was established based on
documented history of myocardial infarction (MI) or posi-
tive results of ECG stress test or gated single photon emis-
sion computed tomography with Tc-99 m-MIBI (SPECT)
or coronary angiography. Peripheral artery disease was
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MI, ischemic stroke or previous revascularization was
established based on medical records. Diabetic nephropa-
thy (DN) was defined as macroalbuminuria (albumin to
creatinine ratio [ACR] >34 mg/mmol [300 mg/g]), or
microalbuminuria (ACR 3.4 to 34 mg/mmol [30 to
300 mg/g]) associated with retinopathy. Diabetic neur-
opathy was diagnosed according to the Toronto Diabetic
Neuropathy Expert Group definition [25]. An experienced
ophthalmologist diagnosed diabetic retinopathy.
The study was powered to have an 90% chance of de-
tecting a 10% difference in plasma clot permeability be-
tween patents with asymptomatic low (<4.5 mmol/L)
and normal (>4.5 mmol/L) FBG using a P value of 0.05,
based on the values of fibrin features in the published
article [26]. In order to demonstrate such a difference
or greater, 30 patients were required in each group. For
a P value of 0.01, 43 patients per group were required.
The local ethics committee approved the study. All
subjects enrolled provided written, informed consent.
Laboratory investigations
Fasting blood samples were drawn between 8:00 and
10:00 AM from an antecubital vein. Plasma samples (9:1
of 3.2% trisodium citrate) for the hemostasis assay were
centrifuged (20 minutes, 2500 g) within 30 minutes of
collection, immediately frozen, and stored in aliquots
at −80°C. Routine blood tests, including glucose (the
hexokinase method), lipid profile, blood cell count,
transaminases, and serum creatinine were carried out
by automated laboratory techniques.
According to FBG patients were divided into 3 groups:
with LOWER glucose (<4.5 mmol/l), with MEDIUM
glucose (4.5-6.0 mmol/l) and with HIGHER glucose
(>6.0 mmol/l). The lower cut-off values was chosen arbi-
trarily, but there were based on the data from DECODE
study demonstrating that subjects with FBG <4.50 mmol/l
in comparison to FBG 4.50–6.09 mmol/l had higher car-
diovascular and total mortality in the follow-up [6].
HbA1C and high sensitivity C-reactive protein (CRP)
were measured using immunoturbidimetric assays (Roche
Diagnostics GmbH, Mannheim, Germany, Tina-quant
Hemoglobin A1c Gen.2 and Cardiac C-Reactive Protein
[Latex] High Sensitive, respectively). Fibrinogen was deter-
mined with the von Clauss method. Plasminogen and
antiplasmin were measured by chromogenic assays (STA
Stachrom plasminogen and STA Stachrom α2-antiplasmin,
Diagnostica Stago, Asniéres, France). Using commercially
available enzyme-linked immunoabsorbent assays, we de-
termined in plasma PAI-1 antigen (PAI-1: Ag) (American
Diagnostica, Stamford, CT, USA), thrombin-activatable fi-
brinolysis inhibitor (TAFI) antigen (Chromogenix, Lexing-
ton, MA, USA) and plasma markers of platelet activation:
soluble CD40 ligand (sCD40L), platelet factor-4 (PF4)(R@D systems). The interassay and intraassay coeffi-
cients of variation for all the ELISAs were <8%.
Thrombin generation potential
To assess plasma thrombogenic potential, the thrombo-
gram was analyzed using the CAT (Thrombinoscope BV,
Maastricht, the Netherlands) according to the manu-
facturer's instructions in the 96-well plate fluorometer
(Ascent Reader, Thermolabsystems OY, Helsinki, Finland)
equipped with the 390/460 filter set at a temperature of
37°C [15]. Each plasma sample was analyzed in duplicate,
and the intraassay variability was 6%. The peak thrombin
level was analyzed.
Fibrin clot permeability
Fibrin clot permeation properties were determined as
previously described [26,27]. A permeation coefficient
(Ks), which indicates the size of fibrin clot pores, was
calculated from the following equation: Ks = Q × L × η/
t × A × Δp, where Q is the flow rate in time t, L is the
length of a fibrin gel (13 mm), η is the viscosity of the
liquid (1/100 poise), A is a cross-sectional area
(0.049 cm2), and Δp is a differential pressure (in dyne/cm2).
The interassay and intraassay coefficients of variation
were <9% (n = 20).
Plasma clot lysis assays
Plasmin-mediated fibrinolysis in the presence of recombin-
ant tissue plasminogen activator (Boehringer Ingelheim,
Ingelheim, Germany) was evaluated as previously described
[26,27]. Lysis time was defined as the time required for a
50% decrease in fibrin clot absorbance (t50%) and was
chosen as a marker of the clot susceptibility to fibrinolysis.
The interassay and intraassay coefficients of variation were
below <8%.
In the second assay, fibrin clots, formed as described
above, were perfused with the same buffer containing
0.2 μmol L-1 rt-PA according to Collet et al. [28]. The
lysis rate was determined by measuring the concentra-
tion of D-dimers (American Diagnostica), a marker of
plasmin-mediated fibrin degradation, in the effluent
every 20 min. The maximum rate of increase in D-dimer
levels (D-Drate, mg/L/min) and maximum D-dimer con-
centrations (D-Dmax) were determined in each subject
(intraindividual variability, 8%). The experiment was
stopped usually after 80–120 min when the fibrin gel
collapsed under the pressure.
Turbidity measurements
We determined the lag phase, which reflects the time
required for fibrin protofibrils to grow to sufficient
length to allow lateral aggregation and maximum ab-
sorbance at plateau (ΔAbsmax), which reflects the num-
ber of protofibrils per fiber, as previously described [29].
Gajos et al. Cardiovascular Diabetology  (2015) 14:44 Page 4 of 12The coefficients of interassay and intraassay variations
were from 5.5 to 7.2%.Statistical analysis
Statistical analyses were performed with SPSS 20.0 soft-
ware. Continuous variables are expressed as mean ± SD
or median (interquartile range) and categorical variables
as number (percentage). Continuous variables were first
checked for normal distribution by the Shapiro-Wilk
statistic. Analysis of variance followed by Bonferroni
test was used to compare differences in the three groups
with normally distributed data whereas non-normally
distributed data were analyzed by Kruskal-Wallis test
and differences between groups were identified using a
test for multiple comparisons of mean rank. Categorical
variables were compared by chi-square test. The J-shape
relationship between fibrin clot permeability (y1), lysis
time (y2), peak thrombin generation (y3) versus fasting
bood glucose concentration (x) was evaluated on the
basis of generalized linear model. The studied rela-
tionships were best fitted with quadratic polynomial
equation (y = β0 + β1 × x + β2 × x
2). The Pearson or
Spearman rank correlation coefficients were calculated
to test the association between two variables with a
normal or non-normal distribution, respectively. Ana-
lysis of covariance assuming homogeneity of slopes
was used to compare fibrin clot properties and throm-
bin generation in the study groups with adjustment
for age, fibrinogen and diabetes duration. All clinical,
laboratory and angiographic variables that showed the
association with clot permeability or lysis time in uni-
variate model and did not show significant correla-
tions with another independent variable were then
included in the multiple regression analysis to deter-
mine predictors of fibrin clot properties and thrombin
generation. A two-sided P < 0.05 was considered statis-
tically significant.Results
One hundred sixty five patients with type 2 diabetes
were included and 38 had low FBG levels, with no se-
vere and symptomatic hypoglycemia in the LOWER glu-
cose group (median 4.0 mmol/l; IQR 3.6-4.2) (Table 1).
The three groups did not differ in terms of demographic
variables, cardiovascular risk factors, medications and
baseline laboratory investigations except HbA1 level
that was lower and insulin use which was lower in
MEDIUM glucose group in comparison with other
groups (Table 1). Patients in the LOWER glucose group
showed a nonsignificant trend to higher hematocrit
values and to a higher prevalence of nephro- and neur-
opathy than individuals in the remaining groups
(Table 1).Thrombin generation and platelet activation markers
A non-linear significant J-shape relationship between
glycemia and peak thrombin generation was found in
the whole group (β0 = 429, β1 = −46.6, β2 = 2.6, p < 0.001
for each component, Figure 1A) and also in patients with
HbA1c > 6.5% (β0 = 525, β1 = −66.4, β2 = 3.6, p < 0.001 for
each component, Figure 1D). The highest peak thrombin
generation was observed in patients in LOWER glucose
group (p = 0.002). Those patients with low glycemia had
21.3% and 15.7% higher thrombin generation in compari-
son to the MEDIUM and HIGHER glucose groups, re-
spectively (p < 0.001 for both) (Table 2).
Plasma PF4 levels were similar in all the three groups
(Table 2). There was a trend towards higher sCD40L in
patients with LOWER glucose as compared to normo-
and hyperglycemic patients (Table 2).
Fibrinolytic proteins
Plasminogen and antiplasmin levels were unaffected by
FBG levels. Interestingly, the highest TAFI levels were
observed in patients in the HIGHER glucose group. They
were 40% and 10% higher than in patients with LOWER
and MEDIUM glucose, respectively (both p < 0.0001).
Fibrin clot formation, porosity and lysis
Interestingly, we observed also a J-shape relationship
between FBG levels and both fibrin clot permeability
(β0 = 5.24, β1 = 0.52, β2 = −0.03, p < 0.001 for each com-
ponent, Figure 2A) and lysis time (β0 = 11.82, p < 0.001;
β1 = −0.55, p = 0.003; β2 = 0.03, p = 0.004, Figure 3A).
The highest Ks and the shortest t50% were found in the
MEDIUM glucose group (Table 2). As compared to
patients from the latter group, Ks was lower by 11%
(p < 0.001) and t50% was prolonged by 10% in patients
with LOWER glucose (p < 0.001) (Table 2). In con-
trast, there were no differences in fibrin clot perme-
ability and lysis time between MEDIUM glucose group
and patients with HIGHER glucose values. There was a
significant J-shape relationship betwen fasting bood
glucose versus Ks (β0 = 4.96, p < 0.001; β1 = 0.61, p =
0.002; β2 = −0.04, p = 0.002) and t50 (β0 = 12.0, p <
0.001; β1 = −0.64, p = 0.008; β2 = 0.04, p = 0.007) in
T2DM patients treated without insulin (Figure 4A) but
not on insulin (Figure 4B).
In patients with HbA1c > 6.5% significant J-shape rela-
tionships between FBG versus Ks (β0 = 5.08, p < 0.001;
β1 = 0.47, p = 0.006; β2 = −0.03, p = 0.007; Figure 2D) and
t50% (β0 = 12.1, p < 0.001; β1 = −0.49, p = 0.018; β2 = 0.03,
p = 0.036; Figure 3D) have been found. In patients with
HbA1c < 6.0% (42 mmol/l), there was a positive linear
correlation between glycemia and Ks (r = 0.53, p = 0.006,
Figure 1B) and an inverse correlation between glycemia
and t50% (r = −0.46, p = 0.02, Figure 2B). In the LOWER
glucose group we observed slightly prolonged lag phase
Table 1 Baseline characteristics and laboratory investigations
LOWER glucose group
(<4.5 mmol/l) N = 38
MEDIUM glucose group
(4.5-6.0 mmol/l) N = 52
HIGHER glucose group
(>6.0 mmol/l) N = 75
P-value
Female, n (%) 15 (39.5) 27 (51.9) 30 (40.0) 0.35
Age, yrs 67 (59–72) 68 (63–73) 66 (59–73) 0.63
Weight, kg 86 (75–100) 84 (75–92) 86 (78–95) 0.24
Height, cm 169 (163–175) 165 (158–170) 168 (158–173) 0.11
BMI, kg/m2 30.8 (26.1-33.7) 31.4 (27.5-35.8) 31.9 (28.4-36.1) 0.17
Waist, cm 107 (93–112) 106 (98–112) 107 (99–113) 0.90
Hip, cm 109 (99–116) 109 (102–115) 109 (104–116) 0.85
Duration of DM, yrs 8 (3–10) 5 (3–7) 5 (3–11) 0.10
CAD, n (%) 24 (63.2) 33 (63.5) 43 (57.3) 0.74
Previous MI, n (%) 9 (23.7) 7 (13.5) 10 (13.3) 0.31
Hypertension, n (%) 35 (92.1) 49 (94.2) 74 (98.7) 0.21
Current smoking, n (%) 4 (10.5) 3 (5.8) 7 (9.3) 0.69
History of smoking, n (%) 17 (44.7) 25 (48.1) 36 (48.0) 0.94
Family history of CAD, n (%) 15 (39.5) 13 (25.0) 16 (21.3) 0.11
Retinopathy, n (%) 4 (10.5) 7 (13.5) 13 (17.3) 0.61
Nephropathy, n (%) 10 (26.3) 4 (7.7) 14 (18.7) 0.06
Neuropathy, n (%) 13 (34.2) 9 (17.3) 13 (17.3) 0.08
Pharmacotherapy
Sulphonylourea, n (%) 17 (44.7) 23 (44.2) 30 (40.0) 0.85
Biguanide, n (%) 23 (60.5) 35 (67.3) 48 (64.0) 0.80
Insulin therapy, n (%) 15 (39.5) 5 (9.6) 24 (32.0) 0.002
Beta-blocker, n (%) 26 (68.4) 39 (75.0) 63 (84.0) 0.15
ACEI, n (%) 30 (78.9) 35 (67.3) 56 (74.7) 0.44
Calcium antagonist, n (%) 14 (36.8) 21 (40.4) 25 (33.3) 0.72
Clopidogrel, n (%) 1 (2.6) 4 (7.7) 4 (5.3) 0.58
Aspirin, n (%) 33 (86.8) 39 (75.0) 61 (81.3) 0.37
Statin, n (%) 35 (92.1) 43 (82.7) 57 (76.0) 0.11
Laboratory results
FBG mmol/l 4 (3.6-4.2) 5.35 (4.9-5.7) 7.3 (6.4-8.3) <0.0001
HbA1c, % 6.7 (6.1-7.3) 6.2 (6.0-6.7) 6.8 (6.3-7.6) 0.0002
HbA1c, mmol/mol 50 (43–56) 44 (42–50) 51 (45–60) 0.0002
WBC, x109/L 6.5 (5.2-7.9) 7.1 (6.2-8.2) 7.3 (6.2-7.9) 0.23
Hemoglobin, g/dL 13.5 (12.9-14.5) 13.8 (13.2-14.4) 13.7 (13.0-14.6) 0.64
Hematocrit, % 43.0 (39.0-46.0) 41.7 (39.9-43.3) 41.2 (39.1-43.2) 0.07
Platelet count, x109/L 227 (176–252) 206 (172–252) 216 (186–266) 0.61
INR 0.99 (0.96-1.08) 0.98 (0.95-1.03) 0.98 (0.94-1.02) 0.18
Creatinine, μmol/L 76 (66–91) 81 (63–92) 79 (66–98) 0.56
Alat, IU/L 21 (12–27) 20 (13–29) 22 (16–30) 0.10
Aspat, IU/L 24 (18–28) 20 (16–25) 20 (18–26) 0.62
TC, mmol/L 4.17 (3.42-4.98) 4.20 (3.51-5.04) 4.43 (3.68-5.32) 0.10
LDL-C cholesterol, mmol/L 2.20 (1.71-2.80) 2.26 (1.92-3.04) 2.57 (2.06-3.41) 0.16
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HDL-C cholesterol, mmol/L 1.11 (0.88-1.35) 1.40 (1.18-1.62) 1.35 (1.08-1.59) 0.08
TG, mmol/L 1.16 (0.94-1.80) 1.31 (0.92-1.56) 1.48 (1.01-1.96) 0.37
hsCRP, mg/dl 2.57 (0.89-5.01) 1.85 (1.02-3.21) 2.29 (1.04-5.08) 0.31
Values are given as mean ± SD, median (interquartile range).
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; Alat, alanine transaminase; Aspat, aspartate transaminase; BMI, body mass index; CAD, coronary artery
disease; FBG, fasting blood glucose; hsCRP, high sensitivity C-reactive protein; DM, diabetes mellitus; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein
cholesterol; INR, International normalized ratio; MI, myocardial infarction; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; WBC, white
blood cells.
Gajos et al. Cardiovascular Diabetology  (2015) 14:44 Page 6 of 12and lower ΔAbsmax compared with other patients. D-Drate
and D-Dmax were similar in the three groups (Table 2).
Correlations
In the whole group both peak thrombin generation and
PF4 were inversely correlated with Ks (r = −0.51, p < 0001
and r = −0.55, p < 0.0001 respectively, Figure 5). Moreover,
peak thrombin generation was negatively correlated with
D-Drate, TAFI and plasminogen and positively correlated
with t50% and D-Dmax (Table 3). Simultaneously, PF4 and
sCD40L were inversely correlated with D-Drate and posi-
tively correlated with t50%, D-Dmax and ΔAbsmax (Table 3).
Independent predictors of fibrin clot phenotype
The multiple regression analysis was used to determine
independent predictors of fibrin clot properties and peak
thrombin genertion (Table 4). Before the inclusion to the
multiple analysis model, independent variables including
age, gender, duration of diabetes mellitus, height, hip
measurement, treatment with aspirin, HbA1c, plateletFigure 1 Peak thrombin generation in relation to glucose and HbA1c leve
glucose [FBG] for the whole group. (B)-(D) Peak thrombin generation in re
P-values for (A) and (D) are in the text of manuscript.count, fibrinogen, glucose concentration and glucose con-
centration squared, PF4 and CD40L were associated in an
univariate model with clot permeability. Gender, duration
of diabetes mellitus, hip measurement, treatment with as-
pirin, HbA1c level, fibrinogen, triglycerides, glucose con-
centration and glucose concentration squared, PF4 and
CD40L were associated with t50%. In turn, age, duration of
diabetes mellitus, treatment with aspirin, HbA1c, fibrino-
gen, glucose concentration and glucose concentration
squared were associated with peak thrombin generation.
After adjustment for fibrinogen (F = 20.9, df = 1, P <
0.0001), HbA1c (F = 11.2, df = 1, P = 0.001), T2DM
duration (F = 8.4, df = 1, P = 0.004) and insulin therapy
(F = 1.8, df = 1, P = 0.18), glucose concentration signifi-
cantly influenced clot permeability (F = 6.6, df = 2, P =
0.002). By multiple analysis, the higher level of fibrinogen,
HbA1c or PF4, and the longer time of DM, the more
dense fibrin network. Also both low and high glucose con-
centrations were associated with lower clot permeability
(Table 4, Figure 2A).l. (A) Peak thrombin generation [PTG] in relation to fasting blood
lation to fasting glucose depending on the various levels of HbA1c.
Table 2 Coagulation, platelet function, fibrinolysis and fibrin clot properties
LOWER glucose group
(<4.5 mmol/l)
MEDIUM glucose group
(4.5-6.0 mmol/l)
HIGHER glucose group
(>6.0 mmol/l)
P-value
Fibrinogen, g/dL 3.06 (2.66-3.48) 3.13 (2.67-3.57) 3.15 (2.64-3.61) 0.98
Peak thrombin, nM 273 (209–380) 225 (201–268)* 236 (196–275)* 0.002
PF4 10.6 (9.1-12.8) 9.5 (8.2-12.0) 10.3 (8.2-12.8) 0.26
sCD40L 4.3 (3.6-4.9) 3.7 (3.1-4.4) 3.8 (3.3-4.8) 0.09
TAFI, % 71.5 (41.6-90.0) 91.0 (84.0-106.0)* 100.0 (92.0-111.0)* <0.0001
PAI-1: Ag 30.6 (25.8-36.1) 32.0 (28.7-36.3) 33.9 (29.4-38.9) 0.23
Plasminogen, % 109 ± 21 108 ± 16 110 ± 14 0.83
Antiplasmin, % 109 (100–118) 109 (96–118) 107 (97–117) 0.61
Ks, cm
2x10−9 6.52 ± 0.79 7.29 ± 0.81* 7.06 ± 0.88* 0.0001
t50%, min 10.49 ± 0.97 9.55 ± 0.91* 9.79 ± 1.11* <0.0001
Lag_phase, s 45 (41–50) 44 (41–47.0) 43 (40–45)* 0.019
ΔAbsmax, 405 nm 0.79 (0.76-0.83) 0.81 (0.77-0.86) 0.82 (0.80-0.87)* 0.015
D-Drate mg/L/min 0.069 ± 0.006 0.070 ± 0.005 0.07 ± 0.004 0.47
D-Dmax mg/L 3.90 (3.78-4.22) 3.87 (3.69-4.06) 3.88 (3.62-4.22) 0.30
Values are given as mean ± SD, median (interquartile range). P value was measured using analysis of variance (ANOVA) with post-hoc Bonferroni test or
Kruskal-Wallis test with multiple comparisons of mean rank, *p < 0.05 as compared with LOWER glucose group.
Abbreviations: ΔAbsmax, maximum absorbance of fibrin gel at 405 nm determined by using turbidimetry; sCD40L, soluble CD40 ligand; D-Dmax, maximum D-dimer
levels in the lysis assay; D-Drate, maximum rate of increase in D-dimer levels in the lysis assay; Ks, permeability coefficient; PAI-1: Ag; plasminogen activator
inhibitor-1 antigen; PF4, platelet factor 4; t50%, half-lysis time; TAFI, thrombin-activatable fibrinolysis inhibitor.
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0.0001), HbA1c (F = 9.5, df = 1, P = 0.003), T2DM
duration (F = 10.5, df = 1, P = 0.001) and insulin ther-
apy (F = 1.6, df = 1, P = 0.21), glucose concentration
significantly influenced clot lysis time (F = 8.0, df = 2,Figure 2 Clot permeability in relation to glucose and HbA1c level. (A) Clot
whole group. (B)-(D) Ks in relation to fasting glucose depending on the va
of manuscript.P = 0.0005). By multiple analysis, the higher level of
fibrinogen, HbA1c or PF4, and the longer time of DM,
the longer time of clot lysis. Also both low and high
glucose concentrations were associated with prolonged
lysis time (Table 4, Figure 3A).permeability [Ks] in relation to fasting blood glucose [FBG] for the
rious levels of HbA1c. P-values for (A) and (D) are in the text
Figure 3 Clot lysis time in relation to FBG and HbA1c level. (A) Lysis time [t50%] in relation to fasting glucose for the whole group. (B)-(D) t50%
in relation to fasting blood glucose [FBG] depending on the various levels of HbA1c. P-values for (A) and (D) are in the text of manuscript.
Figure 4 Ks and t50% versus glucose, according to insulin treatment.
T2DM patients without (A) and with (B) insulin treatment. P-values for
(A) are in the text of manuscript. Abbreviations: as Figures 1 and 2.
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0.003), HbA1c (F = 3.2, df = 1, P = 0.08), T2DM duration
(F = 6.7, df = 1, P = 0.01) and insulin therapy (F = 2.2, df =
1, P = 0.14), glucose concentration significantly influenced
peak thrombin generation (F = 13.5, df = 2, P < 0.0001). By
multiple analysis, the younger patient, the higher level of
fibrinogen, HbA1c, and the longer time of DM, the higher
peak thrombin generation. Also both low and high glucose
concentrations were associated with high peak thrombin
generation (Table 4, Figure 1A).
Discussion
Fibrin clot properties
The current study demonstrates that even asymptomatic
mild hypoglycemia in type 2 diabetes patients with high
CV risk is associated with unfavorably altered plasma fi-
brin clot structure and lysability. We found that type 2
diabetes patients with FBG levels below 4.5 mmol/l
tended to form more compact plasma clots displaying
relative resistance to lysis as compared to those with
higher glycemia. This held true also after adjustment for
fibrinogen, HbA1c, diabetes duration and insulin treat-
ment. Interestingly, fibrin clot properties in type 2 dia-
betes patients demonstrate a J-shape relationship to
their plasma glucose. Additionally, we observed that only
in subjects with HbA1c between 6.0% and 6.5% there
was no negative effect of hypoglycemia on clot perme-
ability and lysis. Moreover, we demonstrated that FBG
levels below 4.5 mmol/l were also associated with en-
hanced thrombin generation and trend towards higher
Figure 5 The relationships between clot permeability and thrombin
generation and platelet function. (A) Ks and peak thrombin generation.
(B) Ks and platelet factor-4 (PF4). Abbreviations: as Table 1 and Figure 1.
Table 3 Fibrin clot properties in relation to fibrinogen,
platelet function and thrombin generation
Fibrinogen Peak thrombin PF4 sCD40L
Ks r = −0.34 r = −0.51 r = −0.55 r = −0.37
p < 0.0001 p < 0.0001 p < 0.0001 p < 0.0001
t50% r = 0.32 r = 0.41 r = 0.41 r = 0.37
p < 0.0001 p < 0.0001 p < 0.0001 p < 0.0001
D-Dmax r = 0.33 r = 0.21 r = 0.17 r = 0.23
p < 0.0001 p = 0.007 p = 0.031 p = 0.003
D-Drate r = −0.53 r = −0.25 r = −0.15 r = −0.18
p < 0.0001 p = 0.001 p = 0.056 p = 0.019
lag phase r = −0.01 r = 0.16 r = −0.05 r = −0.06
p = 0.85 p = 0.035 p = 0.54 p = 0.48
ΔAbsmax r = 0.16 r = −0.04 r = 0.23 r = 0.11
p = 0.044 p = 0.63 p = 0.003 p = 0.14
TAFI r = −0.05 r = −0.51 r = −0.04 r = −0.17
p = 0.56 p < 0.0001 p = 0.64 p = 0.037
Plasminogen r = −0.13 r = −0.22 r = 0.07 r = 0.12
p = 0.11 p = 0.005 p = 0.36 p = 0.15
Antiplasmin r = −0.27 r = −0.06 r = 0.01 r = −0.01
p = 0.001 p = 0.47 p = 0.89 p = 0.97
Abbreviations: as in Tables 1 and 2.
Gajos et al. Cardiovascular Diabetology  (2015) 14:44 Page 9 of 12platelet activation, which might contribute to prothrom-
botic fibrin clot phenotype in this clinical setting. Our
study is the first to demonstrate such prothrombotic ef-
fects in well-treated type 2 diabetes patients with high
CV risk.
Although clot lysis time (t50%) was markedly prolonged
in patients with low glycemia, another marker of fibrin-
olysis, i.e. D-Drate was not affected. The former assay, in
which coagulation is initiated by addition of human
thrombin, together with rt-PA, appears to be more sensi-
tive to glycemia-related alterations to fibrin properties as
compared to the other approach, in which a formed
plasma fibrin clot is subjected to relatively high concen-
trations of rt-PA. Effects of lysis time modifiers including
body-mass index, and C-reactive protein [30] or de-
creased fibrinolysis inhibitor (TAFI) levels could also be
detectable in assays in which fibrin formation is simul-
taneously initiated with fibrinolysis mimicking to some
extent the in vivo situation. Of note, increased levels ofPAI-1 and TAFI have been demonstrated to be involved
in prothrombotic changes in hemostasis observed in dia-
betic patients [15]. However, in the current study in
asymptomatic mild hypoglycemia these two fibrinolysis
inhibitors appear to be of minor importance in hypofi-
brinolysis reported by us.
Importantly, altered plasma clot properties in patients
with low blood glucose were apparent despite adminis-
tration of aspirin, statins and angiotensin converting
enzyme inhibitors (ACEI), which could favorably alter fi-
brin clot structure and function [14]. Given the fact that
most of the patients studied were taking aspirin, ACEI
and a statin, it might be hypothesized that the impact of
low glucose on fibrin clots is potent enough to be
detectable despite some beneficial effects attributed to
those medications.
Thrombin generation
Of particular importance is that in our study alterations
to fibrin clot properties demonstrated in type 2 diabetes
patients, particularly in hypoglycemia, were accompanied
by an increase in peak thrombin generated in plasma sam-
ples, which is a novel observation. The CAT method used
in our study is commonly considered the best measure of
thrombin generation [31]. The peak thrombin generation
was correlated with clot permeability and lysis in the
current type 2 diabetes patients, which supports the con-
cept that the magnitude of thrombin formation is a potent
Table 4 The multiple regression analysis with clot permeability and lysis time as the dependent variables
Dependent variable Independent variables P-value Coefficient 95.0% CI
Clot permeability PF4 <0.001 −0.46 −0.57 −0.33
R = 0.62, R2 = 0.38, Fibrinogen <0.001 −0.27 −0.41 −0.12
F(6, 156) = 13.8, p < 0.0001 HbA1c 0.002 −0.19 −0.33 −0.04
DM duration 0.005 −0.22 −0.36 −0.07
Glucose 0.002 0.61 0.50 0.70
Glucose squared 0.008 −0.56 −0.66 −0.44
Lysis time PF4 <0.001 0.41 0.27 0.53
R = 0.58, R2 = 0.34, Fibrinogen <0.001 0.22 0.07 0.36
F(6, 156) = 11.4, P < 0.0001 DM duration 0.002 0.25 0.10 0.39
HbA1c 0.002 0.20 0.05 0.34
Glucose 0.008 −0.47 −0.58 −0.32
Glucose squared 0.045 0.30 0.15 0.43
Peak thrombin generation Glucose <0.001 −0.97 −0.98 −0.96
R = 0.51, R2 = 0.26, Glucose squared 0.014 0.83 0.77 0.87
F(6, 155) = 8.8, P < 0.0001 Fibrinogen 0.002 0.22 0.07 0.36
DM duration 0.005 0.21 0.06 0.35
HbA1c 0.015 0.21 0.06 0.36
Age 0.03 −0.15 −0.30 0
Abbreviations: as in Tables 1 and 2.
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vascular disease [32]. Therefore, we might assume that
hypoglycemia-induced thrombin generation might largely
contribute to prothrombotic effects in patients with type 2
diabetes and its complications.
The adverse effect of low blood glucose on thrombin
generation and clot structure may have a significant im-
pact on other blood cells. It has been recently shown that
red blood cell (RBC) ultrastructure is altered in diabetic
patients, where these cells are elongated and twist around
spontaneously formed fibrin fibers [33]. Moreover, Preto-
rius et al. have shown that RBCs, upon addition of glucose
or thrombin, lose the ability to maintain the discoid shape
and undergo the deformation under the pressure of dense
fibrin fiber networks [34]. Therefore, entrapping of the
RBCs by denser fibrin clot that is formed when blood
glucose is low may contribute to the formation of the
tight fibrin clots. Moreover, a tendency towards higher
hematocrit in the low glucose group in our study could
also contribute to adverse fibrin properties [35].
Platelet activation
In the current study platelet activation has also been
identified as a fibrin-modifying factor that contributes to
the links between low glycemia and prothrombotic state
with altered clot phenotype in type 2 diabetes patients.
Activated platelets release from alpha granules various
proteins, e.g. PF4, which has high affinity for glycosami-
noglycans and exerts pleiotropic effects in hemostasisand thrombosis by, among others, modulating the ef-
fects of heparin-like molecules [36]. Growing evidence,
largely derived from in vitro studies, indicates that
platelet activation reflected by increased levels of PF4
and release of polyphosphates adversely affects fibrin
clot properties including formation of compact net-
works [14,37]. Amelot et al. [38] have demonstrated that
especially PF4 binds to fibrin and profoundly transforms
the structure of the resulting network. This prothrom-
botic mechanism may be relevant in type 2 diabetes
patients with concomitant CAD, since hyperglycemia
activates platelet aggregation, as shown e.g. in patients
with acute myocardial infarction [39]. In our study al-
though there was only a trend towards increased plate-
let activation in hypoglycemia, a significant correlation
inverse correlation between PF4 and Ks was observed.
Moreover, in multivariate analysis PF4 was an independ-
ent predictor of both Ks and t50% in type 2 diabetes,
which suggests that activated platelets directly contrib-
ute to unfavorable fibrin clot phenotype in this disease.
We cannot exclude that this association with PF4 is
in vivo enhanced by a potent and similar effect of poly-
phosphates on fibrin structure [37].
Novelty
We have previously reported that prolonged duration of
type 2 diabetes is associated with increased thrombin
formation, hypofibrinolysis, and prothrombotic fibrin
clot phenotype [15]. This study adds a novel observation
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glucose is associated with increased thrombin generation
and unfavorable clot properties. It is likely that tendency
to form more compact and poorly lysable clots at low
HbA1c mirrors a number of previous symptomatic or
asymptomatic hypoglycemia episodes and shows their
cumulative negative effects. This hypothesis merits further
investigation. On the other hand, insulin administration
that was much more frequently administered in patients
with low glycemia has been shown to improve fibrin clot
phenotype in diabetic subjects at low cardiovascular risk
[40]. Also in our study, in patients with high CV risk
treated with insulin, no adverse effects of both low and
high blood glucose on fibrin clot properties could be
observed.
We might speculate that our results might offer a
potential explanation of the negative results of the AC-
CORD study in the intensive treatment arm, where the
control of glycemia was strict and the frequency of
hypoglycemia was markedly elevated [2]. Moreover, it
might be one of the underlying mechanisms behind the
observation from a recent meta-analysis of trials involving
over 900 000 patients with type 2 diabetes that severe
hypoglycemia is associated with a higher risk of cardiovas-
cular disease [41]. Although moderate hypoglycemia was
not taken into account in that meta-analysis, it might be
hypothesized that in severe hypoglycemia prothrombotic
effects observed by us are even more pronounced.
Limitations
The study has several limitations. The size of the study
population was relatively small. Although duration of
type 2 diabetes was average and glucose control was ad-
equate, it reflected a real-life diabetic population in our
region. However, our findings cannot likely be extrapo-
lated to the patients with extremely high FBG, HbA1c or
type 1 diabetes. Qualitative changes in coagulation
factors occur in diabetes and the fact that quantitative
differences were not found does not mean that no effect
is observed. Our study was based on assessment of the
variables at a single time point only and we did not fol-
low our patients to assess the incidence of thrombotic
events. This analysis should be considered a hypothesis-
generating study and a larger prospective study is
needed to assess the actual links and the importance of
hypoglycemia and clinical events in type 2 diabetes.
In summary, we demonstrated in patients with type 2
diabetes and high cardiovascular risk that a J-shaped re-
lationship appears to exist between glucose levels and
thrombin formation as well as fibrin clot structure
parameters (density of plasma fibrin network and its
lysability). Interestingly, we have found the alterations in
fibrin clot phenotype and the increase in thrombin gener-
ation were even more pronounced that in patients withhyperglycemia. Given a similar relationship between FBG
and cardiovascular mortality in epidemiological studies,
we might hypothesize that repeated periods of asymptom-
atic low glycemia in type 2 diabetes contributes to a pro-
longed prothrombotic state, leading to increased mortality
following hypoglycemia. These findings may enhance our
understanding of the complex mechanisms behind ele-
vated cardiovascular risk associated with type 2 diabetes.
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